📰 Controlled Trial News
Page 3 - Controlled Trial News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Controlled Trial. Real-time updates on events, politics, business and more.
September 20, 2023
1. In this randomized controlled trial, treatment with pegozafermin improved fibrosis in patients with nonalcoholic steatohepatitis (NASH). 2. Treatment with pegozafermin led to increased rates of NASH resolution. Evidence Rating Level: 1 (Excellent) Study Rundown: NASH is a disease characterized by hepatic inflammation and excess fat accumulation with or without fibrosis of the liver. Pegozafermin
September 7, 2023
Annual Scientific Symposium will take place October 23-26 in San Francisco
August 30, 2023
It’s good to eat more vegetables if you want to lose weight. Here are the best vegetables for weight loss that you can add to your diet 2023.
August 8, 2023
Second-Quarter 2023 Results: -- Net Sales of $945.0 Million, Representing Year-Over-Year Growth of 11% Excluding Inflammation Medicines -- -- GAAP Net Income of $127.1 Million; Adjusted EBITDA of...
August 4, 2023
Wondering if red light therapy for weight loss is safe and effective? Here's what you need to know, including the precautions 2023.
July 18, 2023
Tongkat Ali: Benefits, Side Effects And Dosage
July 13, 2023
/PRNewswire/ -- Olympus Corporation, a global medical technology company, announced publication of study data demonstrating that the minimally invasive iTind™...
July 3, 2023
Getting older is a part of life. These foods will help you do so gracefully -- and in great health!
June 30, 2023
Pegozafermin was associated with improvements in fibrosis and could contribute to a resolution of NASH, according to the results of the phase 2b ENLIVEN trial.
June 24, 2023
– ENLIVEN results demonstrated that treatment with pegozafermin 30mg weekly and 44mg every-two-week doses resulted in statistically significant changes on both primary histology endpoints – – New data showed pegozafermin resulted in sig...